Hong Kong Auto Stock News

CARsgen Therapeutics Holdings announced that China’s National Medical Products Administration has approved satricabtagene autoleucel (satri-cel), an autologous Claudin18.2-targeted CAR T-cell therapy, for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior treatments. As the first CAR T-cell therapy approved globally for solid tumors, satri-cel could reshape treatment options in high-burden cancers like...

Country Garden Holdings (SEHK:2007) has reported June contracted sales of about CN¥2.45b, down 13% year-on-year. The company also reported weaker first half sales and its first interest payment under a major offshore debt restructuring. See our latest analysis for Country Garden Holdings. The June sales update and progress on offshore debt restructuring come after a mixed price pattern for Country Garden Holdings, with the share price up 8.67% over one day and 10.59% over seven days, but down...

AGM approvals put Deep Source Holdings in focus Deep Source Holdings (SEHK:990) is back on investors’ radar after shareholders approved new company bye laws, director re elections and refreshed share issue and repurchase mandates at the 30 June Annual General Meeting. See our latest analysis for Deep Source Holdings. Despite the supportive AGM outcome, Deep Source Holdings’ recent trading has been mixed. The 1 day share price return of 7.27% and 7 day share price return of 3.51% stand against...

Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that the first patient has been enrolled in a Phase III trial for Anaprazole Sodium Enteric-coated Tablets in Helicobacter pylori treatment, a development that could influence how investors view the stock. See our latest analysis for Sihuan Pharmaceutical Holdings Group. At a share price of HK$0.89, Sihuan Pharmaceutical Holdings Group has seen a 7-day share price return of 7.23%, but the 90-day share price return is down...

In June 2026, Geely Automobile Holdings reported a 2% rise in total vehicle sales, powered by very large export growth and a 111% year-on-year jump in deliveries from its premium electric brand ZEEKR. This combination of stronger international demand and rapid electric vehicle momentum underscores how Geely is building a broader global footprint beyond its core China market. We’ll now explore how this surge in exports and ZEEKR’s rapid growth could influence Geely’s existing investment...

As global markets navigate mixed economic signals and regional shifts, the Asian stock landscape presents intriguing opportunities for investors. With manufacturing resilience in China and improved sentiment in Japan, identifying undervalued stocks that could potentially benefit from these conditions is crucial for those looking to capitalize on the evolving market dynamics.

As global markets navigate mixed signals, with U.S. small-cap indices like the Russell 2000 experiencing declines and China's manufacturing sector showing resilience, investors are keenly observing Asia's evolving economic landscape. In this environment, identifying promising stocks often involves looking for companies that demonstrate strong fundamentals and adaptability to shifting market conditions.

With inflation trends uneven across regions and central banks sending mixed signals on rate paths, dependable income can feel hard to find. That is where the Dividend Powerhouses screener comes in, focusing on companies with dividend yields above 5% that are covered by current earnings, growing and relatively stable. While policy debates continue around interest rates, growth and inflation, these stocks aim to put cash in your account today. In this article, you will see three stocks from the...

Shanghai MicroPort MedBot (Group) (SEHK:2252) is in focus after its Toumai Remote laparoscopic surgery robot received the EU CE Mark, opening access to more than 30 European markets and providing formal regulatory recognition of remote surgery. See our latest analysis for Shanghai MicroPort MedBot (Group). The Toumai Remote CE Mark news comes as Shanghai MicroPort MedBot (Group)'s 1 day share price return of 1.57% and 7 day share price return of 4.20% contrast with weaker 30 and 90 day share...

Xiamen Yan Palace Bird's Nest Industry Co., Ltd. ( HKG:1497 ), is not the largest company out there, but it saw a...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Man Wah Holdings Limited ( HKG:1999 ) stock is about to trade ex-dividend in 4 days. The ex-dividend date generally...

As global markets navigate a complex landscape marked by mixed performances in major indices and economic data, investors are increasingly turning their attention to Asia, where resilient manufacturing activity and strategic policy measures are shaping the investment climate. In this context, identifying undervalued stocks that trade below their estimated fair value can offer opportunities for those seeking to capitalize on potential market inefficiencies.

It's been a mediocre week for Want Want China Holdings Limited ( HKG:151 ) shareholders, with the stock dropping 17% to...

As Asian markets navigate a mixed landscape with resilient manufacturing activity in China and shifting sentiment in Japan, investors are keenly observing opportunities that may arise. Penny stocks, though often overlooked, present unique prospects for those seeking growth potential within smaller or newer companies. Despite their traditional reputation as speculative investments, some penny stocks demonstrate robust financial health and can offer intriguing opportunities for long-term success.

Sino Biopharmaceutical (SEHK:1177) is back in focus after China’s regulators approved Peceleganan Spray and accepted a new drug application for tecotabart vedotin, LM-302. These are two pipeline milestones in infection control and advanced gastric cancer. See our latest analysis for Sino Biopharmaceutical. Despite the drug pipeline progress, Sino Biopharmaceutical’s share price tells a mixed story. The HK$4.62 close reflects a 1-day share price return of 4.76% and a 7-day gain of 8.45%, set...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn investor attention after new translational research on its sac-TMT and osimertinib combination for EGFR-mutant non small cell lung cancer was published in the journal Cancer Cell. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The latest Cancer Cell publication and wider sac-TMT trial updates arrive as Sichuan Kelun-Biotech Biopharmaceutical trades at HK$467.6, with a year to date share price return of 16.72%...

Baijin Life Science Holdings (SEHK:1466) has posted its latest full year update with first half FY 2026 revenue of HK$55.1 million and EPS of HK$0.0028, while trailing twelve month figures show revenue of HK$89.3 million and EPS of HK$0.0449 loss alongside a net loss of HK$37.9 million. The company has seen recent half year revenue move from HK$70.9 million in 1H FY 2025 to HK$64.7 million in 2H FY 2025 and HK$55.1 million in 1H FY 2026, with EPS shifting from a HK$0.0092 loss to HK$0.0083...

What the 5-year China Government Bond Futures Launch Means for HKEX Hong Kong Exchanges and Clearing (SEHK:388) is in focus after regulators set a target launch date of 3 August 2026 for 5-year China Government Bond Futures in Hong Kong, expanding the exchange's fixed-income toolkit. This planned contract sits alongside Stock Connect, Bond Connect, Swap Connect and MSCI China A50 Connect Index Futures. It gives investors in Chinese bonds another way to manage interest rate risk linked to...

GoFintech Quantum Innovation (SEHK:290) has put fresh numbers on the table for FY 2026, with first half revenue of HK$1.0b and basic EPS of HK$0.029 setting the tone for how the year is shaping up. The company has seen revenue move from HK$21.3m in the first half of 2025 to HK$838.9m in the second half of 2025 and then to HK$1.0b in the first half of 2026. Basic EPS has shifted from a loss of HK$0.0017 to a small profit of HK$0.0012 and then HK$0.029 across the same periods, giving investors...

Seven Elements Investment Holdings (SEHK:1660) has reported its FY 2026 first half results with revenue of HK$84.6 million and basic EPS of HK$0.000063, setting a cautious tone for investors tracking its profitability. The company has seen revenue move from HK$110.8 million in the first half of FY 2025 to HK$87.1 million in the second half of FY 2025 and HK$84.6 million in the latest half. Net income shifted from a loss of HK$7.4 million and HK$70.4 million in those prior halves to a profit...

Rongzun International Holdings Group (SEHK:1780) has reported its FY 2026 first half results with revenue of HK$28.6 million and a loss per share of HK$0.016596, while net income excluding extra items came in at a loss of HK$10.29 million. The company has seen recent periods swing between a loss per share of HK$0.01692 on HK$43.34 million of revenue in the first half of FY 2025 and a small profit per share of HK$0.001525 on HK$45.04 million of revenue in the second half. This sets up a mixed...

DL Holdings Group (SEHK:1709) has reported its FY 2026 results with first half revenue of HK$115.7 million and basic EPS of HK$0.13, against a backdrop of 165.4% year over year earnings growth and an 83.3% trailing net profit margin over the last twelve months. The company has seen revenue move from HK$60.1 million in the first half of FY 2025 to HK$104.2 million in the second half and then to HK$115.7 million in the first half of FY 2026, while basic EPS progressed from HK$0.01 to HK$0.09...

Yeebo (International Holdings) (SEHK:259) has reported fresh numbers for FY 2026, with first half revenue of HK$554.3 million and basic EPS of HK$1.31. These results come alongside trailing 12 month EPS of HK$4.20 and net income of about HK$3.9 billion, which was shaped by a previously disclosed HK$2.6 billion one off gain. Over the past reported periods, revenue has moved from HK$527.3 million in 1H FY 2025 to HK$511.2 million in 2H FY 2025 and then to HK$554.3 million in 1H FY 2026. Over...